QUCY
Mainz Biomed·NASDAQ
--
--(--)
--
--(--)
QUCY fundamentals
During FY 2025, Mainz Biomed (QUCY) reported revenue of 537.08K, a YoY change of -39.92%. Net income was -16.21M, a YoY change of 24.95%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
FY,2019 | FY,2020 | Q1,2021 | H1,2021 | FY,2021 | Q1,2022 | H1,2022 | 9M,2022 | FY,2022 | Q1,2023 | H1,2023 | 9M,2023 | FY,2023 | H1,2024 | FY,2024 | H1,2025 | FY,2025 | TTM |
|---|
Start Date | Jan 1, 2019 | Jan 1, 2020 | Mar 8, 2021 | Jan 1, 2021 | Jan 1, 2021 | Jan 1, 2022 | Jan 1, 2022 | Jan 1, 2022 | Jan 1, 2022 | Jan 1, 2023 | Jan 1, 2023 | Jan 1, 2023 | Jan 1, 2023 | Jan 1, 2024 | Jan 1, 2024 | Jan 1, 2025 | Jan 1, 2025 | -- |
End Date | Dec 31, 2019 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Jun 30, 2024 | Dec 31, 2024 | Jun 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 281.39K -- | 493.56K +75.40% | -- -- | 417.31K -- | 577.35K +16.98% | 100.56K -- | 239.81K -42.54% | 336.60K -- | 529.88K -8.22% | 250.10K +148.70% | 499.05K +108.11% | 680.72K +102.24% | 895.48K +69.00% | 520.77K +4.35% | 893.99K -0.17% | 286.72K -44.94% | 537.08K -39.92% | 537.08K -- |
Sales and Services Revenue | 281.39K -- | 493.56K +75.40% | -- -- | 417.31K -- | 577.35K +16.98% | 100.56K -- | 239.81K -42.54% | 336.60K -- | 529.88K -8.22% | 250.10K +148.70% | 499.05K +108.11% | 680.72K +102.24% | 895.48K +69.00% | 520.77K +4.35% | 893.99K -0.17% | 286.72K -44.94% | 537.08K -39.92% | 537.08K -- |
Cost of Revenue | 342.66K -- | 370.48K +8.12% | -- -- | 64.77K -- | 399.73K +7.89% | 54.14K -- | 112.56K +73.78% | 190.74K -- | 347.73K -13.01% | 111.16K +105.34% | 211.31K +87.73% | 305.79K +60.32% | 385.82K +10.96% | 201.74K -4.53% | 319.11K -17.29% | 97.13K -51.85% | 147.29K -53.84% | 147.29K -- |
Cost of Goods and Services | 342.66K -- | 370.48K +8.12% | -- -- | -- -- | 399.73K +7.89% | -- -- | -- -- | -- -- | 347.73K -13.01% | -- -- | 211.31K -- | -- -- | 385.82K +10.96% | 201.74K -4.53% | 319.11K -17.29% | 97.13K -51.85% | 147.29K -53.84% | 147.29K -- |
Gross Profit | -61.27K -- | 123.08K +300.89% | -- -- | 352.54K -- | 177.62K +44.31% | 46.43K -- | 127.24K -63.91% | 145.85K -- | 182.15K +2.55% | 138.94K +199.25% | 287.74K +126.14% | 374.93K +157.05% | 509.66K +179.80% | 319.04K +10.88% | 574.88K +12.80% | 189.59K -40.57% | 389.79K -32.20% | 389.79K -- |
Operating Expenses | 860.64K -- | 796.80K -7.42% | 39.99K -- | 607.17K -- | 9.90M +1142.75% | 5.68M +14097.81% | 12.71M +1992.77% | 18.20M -- | 26.63M +168.89% | 6.63M +16.71% | 14.70M +15.70% | 20.43M +12.24% | 27.15M +1.98% | 10.13M -31.12% | 19.35M -28.75% | 8.28M -18.22% | 16.53M -14.57% | 16.53M -- |
Selling, General and Administrative Expenses | 610.32K -- | 484.95K -20.54% | -- -- | 401.03K -- | 9.42M +1842.53% | 5.11M -- | 11.91M +2870.68% | 16.50M -- | 21.61M +129.36% | 4.00M -21.76% | 9.22M -22.61% | 12.84M -22.19% | 17.56M -18.71% | 6.88M -25.34% | 13.23M -24.66% | 5.23M -24.08% | 8.93M -32.53% | 8.93M -- |
Selling and Marketing Expenses | 181.46K -- | 110.38K -39.17% | -- -- | -- -- | 962.66K +772.14% | -- -- | -- -- | -- -- | 6.40M +564.50% | -- -- | 3.99M -- | -- -- | 6.16M -3.73% | 2.36M -40.87% | 6.58M +6.87% | 2.35M -0.51% | 3.82M -41.95% | 3.82M -- |
General and Administrative Expenses | 428.86K -- | 374.57K -12.66% | -- -- | -- -- | 8.46M +2157.96% | -- -- | -- -- | -- -- | 15.21M +79.84% | -- -- | 5.23M -- | -- -- | 11.41M -25.01% | 4.52M -13.48% | 6.65M -41.69% | 2.88M -36.39% | 5.11M -23.20% | 5.11M -- |
Research and Development Expenses | 250.32K -- | 311.85K +24.58% | -- -- | 206.15K -- | 481.93K +54.54% | 563.57K -- | 793.49K +284.92% | 1.70M -- | 5.02M +941.50% | 2.63M +365.79% | 5.48M +590.78% | 7.59M +345.89% | 9.59M +91.07% | 3.24M -40.84% | 5.84M -39.12% | 3.06M -5.78% | 4.96M -15.04% | 4.96M -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 2.64M -- | 2.64M -- |
Other Operating Expenses | -- -- | -- -- | 39.99K -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 277.16K -- | -- -- | 0 -100.00% | -- -- |
Operating Income | -921.91K -- | -673.72K +26.92% | -39.99K -- | -254.63K -- | -9.72M -1343.43% | -5.63M -13981.71% | -12.58M -4840.21% | -18.06M -- | -26.44M -171.93% | -6.49M -15.20% | -14.41M -14.58% | -20.05M -11.07% | -26.64M -0.76% | -9.81M +31.96% | -18.77M +29.54% | -8.09M +17.50% | -16.14M +14.03% | -16.14M -- |
Non-Operating Income (Loss) | -35.15K -- | 86.82K +347.03% | -- -- | -7.09K -- | -1.97M -2363.87% | -32.18K -- | -22.98K -224.26% | -143.61K -- | 56.70K +102.88% | -73.36K -127.98% | -399.00K -1636.28% | -1.06M -636.78% | 348.95K +515.40% | -1.22M -204.87% | -2.83M -909.72% | -252.86K +79.21% | -71.62K +97.47% | -71.62K -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 45.00K -- | -- -- | 661.00K -- | -528.21K -1273.80% | -2.05M -410.44% | 21.00K +103.98% | 21.00K +101.02% | 21.00K -- |
Other Non-Operating Income (Loss) | 121.72K -- | 263.24K +116.26% | -- -- | 66.28K -- | -1.63M -717.82% | -32.18K -- | -22.98K -134.67% | -143.61K -- | 346.03K +121.28% | -73.36K -127.98% | -105.24K -357.95% | -1.06M -636.78% | 497.54K +43.78% | -28.75K +72.68% | 171.98K -65.43% | -58.60K -103.83% | 280.84K +63.30% | 280.84K -- |
Net Interest Expense | 156.87K -- | 176.42K +12.46% | -- -- | 73.36K -- | 339.17K +92.26% | -- -- | -- -- | -- -- | 289.32K -14.70% | -- -- | 338.76K -- | -- -- | 809.58K +179.82% | 659.47K +94.67% | 945.54K +16.79% | 215.26K -67.36% | 373.46K -60.50% | 373.46K -- |
Interest Expense | 156.87K -- | 176.42K +12.46% | -- -- | 73.36K -- | 339.17K +92.26% | -- -- | -- -- | -- -- | 289.32K -14.70% | -- -- | 338.76K -- | -- -- | 809.58K +179.82% | 659.47K +94.67% | 945.54K +16.79% | 215.26K -67.36% | 373.46K -60.50% | 373.46K -- |
Pretax Income From Continuing Operations | -957.05K -- | -586.89K +38.68% | -39.99K -- | -261.72K -- | -11.69M -1891.86% | -5.66M -14062.17% | -12.60M -4715.22% | -18.20M -- | -26.39M -125.72% | -6.56M -15.84% | -14.81M -17.54% | -21.11M -16.01% | -26.30M +0.35% | -11.02M +25.58% | -21.60M +17.86% | -8.34M +24.31% | -16.21M +24.95% | -16.21M -- |
Income Tax Expense | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | -- -- |
Other Items Before Net Income | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -150.60K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -957.05K -- | -586.89K +38.68% | -39.99K -- | -261.72K -- | -11.69M -1891.86% | -5.66M -14062.17% | -12.60M -4715.22% | -18.20M -- | -26.39M -125.72% | -6.56M -15.84% | -14.81M -17.54% | -21.11M -16.01% | -26.30M +0.35% | -11.02M +25.58% | -21.60M +17.86% | -8.34M +24.31% | -16.21M +24.95% | -16.21M -- |
Net Income Attributable to Owners of the Company | -957.05K -- | -586.89K +38.68% | -39.99K -- | -261.72K -- | -11.69M -1891.86% | -5.66M -14062.17% | -12.60M -4715.22% | -18.20M -- | -26.39M -125.72% | -6.56M -15.84% | -14.96M -18.73% | -21.11M -16.01% | -26.30M +0.35% | -11.02M +26.33% | -21.60M +17.86% | -8.34M +24.31% | -16.21M +24.95% | -16.21M -- |
Net Income Attributable to Common Stockholders | -957.05K -- | -586.89K +38.68% | -39.99K -- | -261.72K -- | -11.69M -1891.86% | -5.66M -14062.17% | -12.60M -4715.22% | -18.20M -- | -26.39M -125.72% | -6.56M -15.84% | -14.96M -18.73% | -21.11M -16.01% | -26.30M +0.35% | -11.02M +26.33% | -21.60M +17.86% | -8.34M +24.31% | -16.21M +24.95% | -16.21M -- |
Other Comprehensive Income | 22.17K -- | -224.66K -1113.52% | -- -- | 82.96K -- | 204.97K +191.24% | 36.44K -- | 82.64K -0.39% | 146.74K -- | 49.70K -75.75% | -60.57K -266.23% | -150.60K -282.22% | 330.87K +125.48% | -504.49K -1115.02% | -62.37K +58.59% | -96.32K +80.91% | -58.85K +5.63% | -69.02K +28.34% | -69.02K -- |
Total Comprehensive Income | -934.89K -- | -811.55K +13.19% | -39.99K -- | -178.76K -- | -11.49M -1315.21% | -5.63M -13971.06% | -12.52M -6903.77% | -18.05M -- | -26.34M -129.32% | -6.62M -17.67% | -14.96M -19.52% | -20.78M -15.12% | -26.80M -1.76% | -11.09M +25.91% | -21.70M +19.05% | -8.40M +24.20% | -16.28M +24.96% | -16.28M -- |
Total Comprehensive Income Attributable to Owners of the Company | -934.89K -- | -811.55K +13.19% | -39.99K -- | -178.76K -- | -11.49M -1315.21% | -5.63M -13971.06% | -12.52M -6903.77% | -18.05M -- | -26.34M -129.32% | -6.62M -17.67% | -14.96M -19.52% | -20.78M -15.12% | -26.80M -1.76% | -11.09M +25.91% | -21.70M +19.05% | -8.40M +24.20% | -16.28M +24.96% | -16.28M -- |
Basic EPS | -0.17 -- | -0.1 +41.18% | -39.99K -- | -0.05 -- | -1.62 -1520.00% | -0.42 +100.00% | -0.91 -1720.00% | -1.32 -- | -74.55 -4501.85% | -0.45 -7.14% | -1 -9.89% | -1.38 -4.55% | -64.76 +13.13% | -19.73 -1873.00% | -21.91 +66.17% | -2.65 +86.57% | -2.7 +87.68% | -2.7 -- |
Basic EPS from Continuing Operations | -0.17 -- | -0.1 +41.18% | -- -- | -- -- | -1.62 -1520.00% | -- -- | -- -- | -- -- | -74.55 -4501.85% | -- -- | -1 -- | -- -- | -64.76 +13.13% | -19.73 -1873.00% | -21.91 +66.17% | -2.65 +86.57% | -2.7 +87.68% | -2.7 -- |
Diluted EPS | -0.17 -- | -0.1 +41.18% | -39.99K -- | -0.05 -- | -1.62 -1520.00% | -0.42 +100.00% | -0.91 -1720.00% | -1.32 -- | -74.55 -4501.85% | -0.45 -7.14% | -1 -9.89% | -1.38 -4.55% | -64.76 +13.13% | -- -- | -21.91 +66.17% | -- -- | -2.7 +87.68% | -2.7 -- |
Diluted EPS from Continuing Operations | -0.17 -- | -0.1 +41.18% | -- -- | -- -- | -1.62 -1520.00% | -- -- | -- -- | -- -- | -74.55 -4501.85% | -- -- | -1 -- | -- -- | -64.76 +13.13% | -19.73 -1873.00% | -21.91 +66.17% | -2.65 +86.57% | -2.7 +87.68% | -2.7 -- |
You can ask Aime
What were the key takeaways from Mainz Biomed’s earnings call?What is the market's earnings forecast for Mainz Biomed next quarter?What factors drove the changes in Mainz Biomed's revenue and profit?What does Mainz Biomed do and what are its main business segments?What guidance did Mainz Biomed's management provide for the next earnings period?Did Mainz Biomed beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Mainz Biomed year over year?What were the key takeaways from Mainz Biomed's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
